|
|
|
|
|
|
Sponsors and Collaborators: |
Joslin Diabetes Center National Institutes of Health (NIH) |
Information provided by: | Joslin Diabetes Center |
ClinicalTrials.gov Identifier: | NCT00258115 |
Chronic subaccute inflammation may underlie the development of diabetes cardiovascular disease and other components of the metabolic syndrome. Rodent studies suggest diet induced obesity is associated with activation of the IKK/NF-kB pathway and this pathway can be inhibited by salicylates. This study seeks to determine the effect of salicylates in overweight persons.
Condition | Intervention | Phase |
Obesity |
Drug: salsalate |
Phase II |
MedlinePlus related topics: | Diabetes Obesity |
ChemIDplus related topics: | Dextrose Salicylsalicylic acid Sodium salicylate |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity |
Ages Eligible for Study: | 18 Years to 30 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Joslin Diabetes Center | |||||
Boston, Massachusetts, United States, 02215 |
Joslin Diabetes Center |
National Institutes of Health (NIH) |
Principal Investigator: | Allison B. Goldfine, MD | Investigator/Assistant Professor |
Joslin Diabetes Center Web-Site 
  |
Multicenter study to target inflammation using salsalate in type 2 diabetes. 
  |
Study ID Numbers: | CHS 03-48 |
First Received: | November 22, 2005 |
Last Updated: | February 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00258115 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|